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Introduction
Vascular lesions/angioectasia are the most common source of
small bowel (SB) bleeding [1]. Although their pathogenesis is
poorly understood, it is felt to relate to age and strain on the
intestinal wall [2] with chronic hypoperfusion of the bowel hy-
pothesized to contribute [3]. Mid gut bleeding is often precipi-
tated by impaired clotting. This can be through medical antico-
agulation and/or antiplatelet therapy or due to complicated
and poorly understood sequalae of comorbidities, which often
accumulate with age. For example, aortic valve stenosis (AoVS)
is speculated to result in turbulent blood flow, which proteoly-
ses von Willebrand (VWF) factor, and the resultant deficiency
can propagate gastrointestinal bleeding [4]. Chronic kidney
disease (CKD) results in increased bleeding through impaired
platelet function and platelet vessel wall interactions [5, 6]. As
such, presentations with SB bleeding secondary to angioectasia
could be felt to be a marker of frailty with age and comorbidity
leading to initial formation and possible bleeding.
The aim of this study was to review survival in patients diag-
nosed with bleeding SB angioectasia, with the hypothesis that
many will die due to organ failure and comorbidity rather than
gastointestinal bleeding.
Patients and methods
A prospectively populated database of small bowel capsule
endoscopy (SBCE) procedures was retrospectively reviewed for
cases were angioectasia were isolated as the cause of SB bleed-
ing. One hundred twenty-five SBCEs fulfilled the criteria (i. e.
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ABSTRACT
Background and study aims This study aimed to estab-
lish 5-year survival of patients diagnosed with bleeding
small bowel (SB) angioectasia, with the hypothesis that
many will suffer deaths relating to comorbidity rather than
gastrointestinaI bleeding.
Patients and methods SB capsule endoscopy (SBCE) pro-
cedures, performed for suspected SB bleeding or iron defi-
ciency anemia, with angioectasia isolated as the cause of SB
bleeding and at least 5 years of follow-up data were isolated
(n =125) along with an age-matched group with “normal”
SBCE procedures (n =125). These were retrospectively ana-
lysed with further information on mortality and comorbid-
ity gathered through hospital records.
Results Those with angioectasia had a median age of 72.7
years and comorbidities were common. The 5-year survival
was 64.0% (80/125) compared to 70.4% (88/125) in those
with “normal” SBCE. Those with significant cardiac or vas-
cular comorbidity had a poorer survival (52.9% (37/70) at
5 years) but anticoagulation/antiplatelets/ number of le-
sions or requirement endoscopic treatment seemed to
make little difference. In those with SB bleeding secondary
to angioectasia none of the subsequent deaths were direct-
ly attributable to gastrointestinal bleeding.
Conclusions In this cohort, SB angioectasia did not lead to
any deaths but the 5-year survival was poor due to those di-
agnosed often being older and having comorbidities. This
would support the hypothesis that a diagnosis of SB bleed-
ing secondary to angioectasia suggests frailty.
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angioectasia as the cause of SB bleeding and performed prior to
June 2014, ensuring availability of 5-year survival data). They
were retrospectively analysed with further information on the
clinical course, management, number of angioectasia seen
along with mortality and comorbidity gathered through hospi-
tal records.
Data from an age- and gender-matched group with “nor-
mal” SBCE procedures was also extracted. These patients were
also all investigated for iron deficiency anemia or occult gastro-
intestinal bleeding but without any abnormality of the small
bowel identified. Microsoft Excel (Microsoft Corporation, Wa-
shington, United States) was used to collate, analyse and graph
the results.
Results
Demographics and comorbidities
At the time of SBCE, patients with isolated angioectasia had a
median age of 72.7 (IQR 63.2–77.7) years, 69 female: 56 male.
Those with a “normal” SBCE also had a median age of 72.7 (IQR
62.9–78.1) years, again 69 female: 56 male.
Comorbidities were common in both groups and are shown
in ▶Table 1. Cardiac, vascular, and renal disease was more com-
mon in those found to have angioectasia.
Five-year survival
Of the 125 patients with angioectasia on their SBCE, 64 had
died by the end of the study period (June 2019) with 45 of these
deaths within 5 years of their index SBCE (▶Fig. 1). Overall
▶Table 1 Comorbidities.
Comorbidity Angioectasia Normal CE
Number (%) Number (%)
Cardiac/vascular
Ischemic heart disease 28 (22.4) 25 (20)
LVSD/CCF 24 (19.2) 17 (13.6)
Cerebrovascular disease 19 (15.2) 15 (12)
Aortic valve disease ±AVR 18 (14.4) 10 (8)
Atrial fibrillation 14 (11.2) 21 (16.8)
AAA 11 (8.8)  1 (0.8)
Peripheral vascular disease 11 (8.8)  4 (3.2)
Mitral valve disease  3 (2.4)  8 (6.4)
Cardiomyopathy  2 (1.6)  1 (0.8)
Mesenteric ischemia  1 (0.8)  0
Diabetes 30 (24) 23 (18.4)
Dementia
Vascular  3 (2.4)  2 (1.6)
Alzheimer’s  2 (1.6)  3 (2.4)
Mixed  1 (0.8)  2 (1.6)
Liver cirrhosis  9 (7.2)  5 (4.0)
Viral hepatitis  0  2 (1.6)
Crohn's disease  4 (3.2)  0
Pancreatitis  0  2 (1.6)
Renal
Chronic kidney disease 18 (14.4)  9 (7.2)
End stage renal failure/dialysis  4 (3.2)  0
Respiratory
COPD 18 (14.4) 15 (12)
Asthma  4 (3.2)  2 (1.6)
▶Table 1 (Continuation)
Comorbidity Angioectasia Normal CE
Number (%) Number (%)
Bronchiectasis  0  1 (0.8)
Pulmonary fibrosis  0  2 (1.6)
Hereditary hemorrhagic
telangectasia
 3 (2.4)  0
Hematological
Platelet release defect  2 (1.6)  0
ITP  1 (0.8)  0
Myelodysplasia  1 (0.8)  1 (0.8)
Factor V Leiden  1 (0.8)  0
VWF  1 (0.8)  1 (0.8)
MGUS  0  2 (1.6)
Borderline factor XI  0  1 (0.8)
Vasculitis  0  1 (0.8)
Malignancy
Breast  0  4 (3.2)
Bladder  0  1 (0.8)
Vulval  0  1 (0.8)
Rectal  0  1 (0.8)
Prostate  1 (0.8)  2 (1.6)
Melanoma  0  3 (2.4)
Parkinson’s disease  0  1 (0.8)
Hereditary spastic paraplegia  0  1 (0.8)
CE, capsule endoscopy; LVSD, left ventricular systolic dysfunction; CCF,
congestive cardiac failure; AVR, aortic valve replacement; AAA, abdominal
aortic aneurysm; COPD, chronic obstructive pulmonary disease; ITP, im-
mune thrombocytopenic purpura; VWF, von Willebrand factor; MGUS,
monoclonal gammopathy of undetermined significance
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5-year survival was 64.0% (80/125). Median age at death was
78 years (IQR 73–83) in those that died by the end of follow-
up. Five-year survival was 70.4% (88/125 in those with “nor-
mal” SBCE. Median age at death in those who had died by the
end of the study was 81.0 years.
Impact of age and comorbidities
Only 17.6% of patients (22/125) with angioectasia had no ma-
jor comorbidities and they were younger with a median age of
69.3 (IQR 61.0–75.0) years. Eight of 22 had died by the end of
follow-up (June 2019) with a median age of 78 years (IQR 75.5–
78.25). The rate of 5-year survival in those with no major co-
morbidities was 81.1% (18/22), as shown in ▶Fig. 2.
Eighty-nine were over age 65 years with angioectasia, 12
had incomplete notes due to being out of area, and a further
11 had no major comorbidities (including those with uncompli-
cated Type 2 diabetes or hypertension only). This left 66 for a-
nalysis who were aged over 65 (mean age 76.4 years) with at
least one major comorbidity. 28.8% (19/66) were alive at end
of study period (June 2019) with a 5-year survival of 45.5%
(30/66) (▶Fig. 2).
In those with normal SBCE procedures with one or more
major comorbidity and age>65, 5-year survival was 57.4%
(39/68).
Patients with renal, cardiac or vascular comorbidity
Those with angioectasia and renal disease (CKD) had a 5-year
survival of 61.9% (11/19).
Fifty-six percent (70/125) of those with angioectasia causing
their SB blood loss had at least one major cardiac or vascular co-
morbidity (ischemic heart disease, congestive cardiac failure,
cerebrovascular accident, aortic or mitral disease, atrial fibrilla-
tion, abdominal aortic aneurysm, peripheral vascular disease,
cardiomyopathy, mesenteric ischemia, intracerebral bleed).
Those with cardiac/vascular disease had a 5-year survival of
52.9% (37/70). They were slightly older at the time of SBCE
with a median age of 75.5 (interquartile range 68.8–81.8)
years. Those with cardiac/vascular disease taking antiplatelets/
anticoagulants had a 5-year survival of 51.4%, compared to
53.1% in those who were not (one excluded from analysis for
unclear documentation).
Of those without angioectasia, 50.4% (63/125) had cardiac
or vascular comorbidity, and their 5-year survival rate was high-
er at 63.5%.
Causes of death
None of the deaths in those with SB bleeding secondary to an-
gioectasia were documented as being directly attributable to
gastrointestinal bleeding, although a significant number were
from out of area and had incomplete documentation available
following their death (▶Table2).
Two deaths in the group with no SB abnormalities on CE were
due to uncontrolled gastrointestinal bleeding, one case from
rectal varices and one from a gastric ulcer. Both of these deaths
occurred within a month of their normal SBCE investigation.
Number and extent of angioectasia
A clear description of the extent of small bowel angioectatic
disease was present in 71 of the cases. Of them, 41/71 (57.7%)
had one or two angioectasias. The 5-year survival in this group
was 70.7% (29/41). This group had a median age of 70.0 (IQR
61.4–76.1) years, with 28 (68.3%) suffering major cardiac, vas-
cular or renal comorbidity. Sixteen (39.0%) were noted to be
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▶ Fig. 2 Five-year survival in those with no major comorbidities
compared to those >65 years of age with at least one major comor-
bidity following diagnosis of angioectasia .
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▶ Fig. 1 Five-year survival post diagnosis with angioectasia vs those
with “normal” SBCE.
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taking antiplatelets and/or anticoagulants. Thirty of 71 (42.3%)
of them had three or more angioectasias. This group was older
with a median age of 76.2 years (IQR 69.3–80.4), with 19
(63.3%) suffering major cardiac, vascular or renal comorbidity.
Ten (33.3%) were noted to be taking antiplatelets and/or an-
ticoagulants. Their 5-year survival was 66.7% (20/30).
Those with documentation giving an unclear description of
the number of lesions (n =54) were often older and largely
from out of area. These patients had a median age of 71.8 and
a 5-year survival rate of 57.7% (31/54).
Endoscopic treatments given
Of the 125 patients with angioectasia isolated on their SBCE, 37
subsequently had endoscopic treatment with argon plasma co-
agulation (APC) planned (4 procedures later cancelled or
failed): double balloon enteroscopy (DBE) (n =22); push entero-
scopy (PE) (n =5); upper gastrointestinal endoscopy (n =9) and
colonoscopy (n=1). These patients had a median age of 74.1
years. Those who underwent endoscopic therapy had a 5-year
survival rate of 62.2% (23/37).
Discussion
The overall 5-year survival in those diagnosed with angioectasia
on SBCE was 64.0%. This is comparable to the 5-year mortality
rate seen when SB adenocarcinoma (all SEER stages combined)
is diagnosed (68%) and worse than when the cancer is localised
(85% survival at 5 years) [7]. A similar study looking at all caus-
es of occult SB bleeding had a 74.7% 5-year survival rate com-
pared to 89.3% age matched cohort survival in Japan [8]. This
would suggest that a diagnosis of SB angioectasia is both signif-
icant and associated with worse outcomes than serious alterna-
tive pathologies seen.
Those with a “normal” SB on SBCE (age and gender mat-
ched) were used as a comparison and had a 5-year survival
rate of 70.4% (▶Table 3). This is better than those with an-
gioectasia but poorer than might have been expected. At ages
65 to 69 a man in the city of Edinburgh has a life expectancy of
18.0 years, and woman 20.5 years [9]. This could be explained
in several ways. It seems likely that many of these patients will
have had an anemia of chronic disease, which would be suppor-
ted by the higher level of cancer deaths (8.8% vs 2.4% in those
with angioectasia). It is also plausible that a significant number
of those with a “normal” SBCE did in fact have iron deficiency or
bleeding secondary to angioectasia either elsewhere within the
gastrointestinal tract or missed within the small bowel. This
could be suggested by a significant overlap in the comorbidities
and clinical outcomes of the patients. It is possible some of
these patients had pathology in their upper or lower gastroin-
testinal tract that had been missed on investigation. As such,
the inclusion of those investigated for iron deficiency anemia
or small bowel bleeding with a “normal” resultant CE is a poor
control group and could not entirely be taken as such due to the
degree of cohort bias. Ideally there would be an age matched
healthy “control” group, but this is not available.
A reported 47% of elderly people in nursing homes are ane-
mic [10], there is often only cursory investigation to exclude
▶Table 2 List of causes of death.
Pathology Deaths in
those with an-
gioectasia (%)
Deaths in those
without an-
gioectasia (%)
Pneumonia/chest sepsis  7 (5.6)  6 (4.8)
MI  5 (4)  5 (4)
Liver failure (NAFLD)  2 (1.6)  0
COPD/bronchiectasis  2 (1.6)  1 (0.8)
Cancer  3 (2.4) 11 (8.8)
Bladder  1 (0.8)  0
NSCLC  1 (0.8)  3 (2.4)
SCLC  0  2 (1.6)
HCC  0  1 (0.8)
Breast  0  1 (0.8)
Gastric  0  1 (0.8)
Prostate  1 (0.8)  2 (1.6)
Colon  0  1 (0.8)
Following ascitic drain  0  1 (0.8)
Surgical complication  4 (3.2)  0
Renal  1 (0.8)  0
Crohn's resection with de-
hiscence of SB anastomosis
 1 (0.8)  0
Adrenalectomy for Pheo-
chromocytoma
 1 (0.8)  0
Kidney/pancreas transplant  1 (0.8)  0
Ruptured AAA  2 (1.6)  0
CCF secondary to AS  2 (1.6)  1 (0.8)
CVA  2 (1.6)  2 (1.6)
CCF  2 (1.6)  4 (3.2)
Renal failure  2 (1.6)  1 (0.8)
Intracranial hemorrhage  1 (0.8)  2 (1.6)
PE  1 (0.8)  0
Biliary sepsis secondary to
cholangiocarcinoma
 1 (0.8)  0
Ischemic colitis  1 (0.8)  1 (0.8)
Rectal variceal bleed  0  1 (0.8)
Upper gastrointestinal
bleed (gastric ulcer)
 0  1 (0.8)
Unclear/unrecorded (many
out of area)
27 (21.6) 14 (11.2)
Alive 61 (48.8) 74 (59.2)
MI, myocardial infarction; NAFLD, non-alcoholic fatty liver disease; COPD,
chronic obstructive pulmonary disease; NSCLC, non small cell lung carcino-
ma; HCC, hepatocellular carcinoma; SB, small bowel; AAA, abdominal aortic
aneurysm; CCF, congestive cardiac failure; AS, aortic stenosis; CVA, cere-
brovascular accident; PE, pulmonary embolism.
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malignancy undertaken with symptomatic management fol-
lowing this. It is likely that a significant proportion of these pa-
tients will have angioectasia as the underlying pathology. Those
undergoing SBCE are likely to represent a younger, healthier
population, making the high mortality seen more striking and
potentially over-estimating survival following a diagnosis of an-
gioectasia. Despite this, those investigated in this study were
older (median 72.7 years) and often multimorbid (▶Table1).
Although none of the deaths were directly caused by bleed-
ing from angioectasia, it is not unlikely that chronic anaemia
may have contributed to cardiovascular disease, or affected
management options. Those who required endoscopic therapy
following a diagnosis of angioectasia of the SB had almost the
same survival as those who did not (62.2% vs 64.0%). Those
with one or two lesions were younger than those with three or
more (70.0 vs 76.2 years) and had a marginally better 5-year
survival rate (70.1% vs 66.7%).
These results suggest that the degree of angioectatic bleed-
ing was not associated with increased mortality but merely
their presence could be taken as a marker of comorbidity and
frailty.
This study has certain limitations. The retrospective design
relied on data collected from prior to June 2014, with many of
these patients from other health boards having incomplete re-
cords available. The original reports for many, as seen in the re-
sults section, was lacking with variable documentation of the
lesions and clinical course at the time of these procedures.
The small numbers available are due to the specificity of the
cohort being examined, but this does make result difficult to
interpret. This is particularly true for the subgroups, therefore,
generalization of these findings would be less reliable.
Characterization of the initial patient presentation and de-
gree of angioectatic bleeding proved to be difficult. The focus
of this manuscript is on the frailty of those presenting with an-
gioectasia and this proved to complicate the severity markers
investigated. The initial presentations, hemoglobin levels and
transfusion requirements, where recorded, were less reliable
and difficult to interpret as they were affected by confounding
patient factors.
Despite these limitations, this study represents real-world
outcomes in frail and elderly patients who are commonly ex-
cluded from prospectively held research. We feel this is a major
strength of this manuscript.
Five-year survival was poorest in those over 65 with at least
one major comorbidity (45.5%). This is comparable with those
who have metastatic small bowel adenocarcinoma diagnosed
(42% 5 year survival) [7].
Conclusion
As hypothesized, those diagnosed with SB angioectasia are very
frequently elderly and frail, and although the angioectasia did
not cause any documented deaths, the 5-year survival was
poor.
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